Product Introduction
Bioactivity


英文名: Pamidronic acid

描述: Pamidronic acid 可用于各种骨吸收类疾病的研究。

细胞实验: Primary human BMMSCs were isolated from the mandible and marrow tissue. A proliferation assay was performed to determine the experimental concentration of pamidronate disodium. Alkaline phosphatase (ALP) activity, ALP staining, and Alizarin red S (ARS) staining were assessed after treatment with pamidronate disodium (0, 0.1, 0.5, 1, 5, 10 μg/mL). Quantitative real-time polymerase chain reaction and western blotting specific for Wnt and β-catenin signaling genes or proteins were performed after treatment with pamidronate disodium 0.5 μg/mL. Wnt3a was used to observe the osteogenic differentiation of BMMSCs during treatment with pamidronate disodium 0.5 μg/mL[1].

体外活性: Pamidronate disodium inhibited Wnt and β-catenin signaling, which controls osteogenic differentiation in BMMSCs. Wnt3a, a Wnt and β-catenin signaling activator, reversed the negative effects caused by pamidronate disodium to salvage the osteogenic defect in BMMSCs[1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: H2O : 6 mg/mL (25.52 mM)


关键字: inhibit | Inhibitor | β-catenin | Beta catenin | Wnt | Pamidronic acid

相关产品: Wogonin | Excisanin A | GSK-3β inhibitor 8 | β-catenin-IN-2 | DK419 | Gliotoxin | Ergosterol peroxide | Triptonide | MN-64 | NRX-252114

相关库: Anti-Aging Compound Library | Drug Repurposing Compound Library | Anti-Prostate Cancer Compound Library | Anti-Cancer Drug Library | Clinical Compound Library | Neuronal Differentiation Compound Library | Osteogenesis Compound Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Approved Drug Library | Anti-Cancer Active Compound Library